Becton Dickinson and Co
Change company Symbol lookup
Select an option...
BDX Becton Dickinson and Co
GGN GAMCO Global Gold, Natural Resources & Income Trust
GUT Gabelli Utility Trust
CHD Church & Dwight Co Inc
CHY Calamos Convertible & High Income Fund
CHW Calamos Global Dynamic Income Fund
CCVIX Calamos Convertible Fund Class A
ETY Eaton Vance Tax-Managed Diversified Equity Income Fund
ETB Eaton Vance Tax-Managed Buy-Write Income Fund
NEE Nextera Energy Inc
Go

Health Care : Health Care Equipment & Supplies | Large Cap Blend
Company profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.

Closing Price
$241.15
Day's Change
-6.00 (-2.43%)
Bid
--
Ask
--
B/A Size
--
Day's High
247.50
Day's Low
241.01
Volume
(Above Average)
Volume:
1,540,891

10-day average volume:
1,361,894
1,540,891

Palantir's stock gains after new contract with the U.K.'s NHS could be valued at over $31 million

6:57 am ET December 23, 2020 (MarketWatch)
Print

Shares of Palantir Technologies Inc. (PLTR) rose 0.8% in premarket trading Wednesday, after the big-data software company said it signed a new two-year contract with the U.K.'s National Health Service (https://www.contractsfinder.service.gov.uk/Notice/9233a767-bd2b-49eb-9c57-310bb2e259e0). The contract could be valued at up to GBP23.5 million ($31.6 million). The company said the NHS will use Palantir Foundry to understand how COVID-19 spreads and identify risks to particular populations, increase health and care resources in emerging hot spots, supply equipment to to the facilities with the greatest need and divert patients and service users to facilities best able to respond. Palantir's stock has rocketed 195.2% since it closed at $9.50 on its first day of trading on Sept. 30, while the S&P 500 has gained 9.6% over the same time.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

	

(END) Dow Jones Newswires

December 23, 2020 06:57 ET (11:57 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.